Global Patient Week Our Medicines Contact Us Careers
United States
Americas

Argentina

Spanish

Brazil

Portuguese

Canada

English French

Chile

Spanish

Colombia

Spanish

Mexico

Spanish

Peru

Spanish

United States

English
Asia Pacific

Australia

English

China

Simplified Chinese

India

English

Japan

Japanese

Korea

Korean

New Zealand

English

Singapore

English

Taiwan

Traditional Chinese

Thailand

English Thai
Europe

Austria

German

Belgium

English Dutch French

Czech Republic

Czech

Denmark

Danish

Finland

Finnish

France

French

Germany

German

Greece

Greek

Hungary

Hungarian

Ireland

English

Italy

Italian

Luxembourg

English

Netherlands

English Dutch

Norway

Norwegian

Poland

Polish

Portugal

Portuguese

Romania

Romanian

Spain

Spanish

Sweden

Swedish

Switzerland

German French

United Kingdom

English
Middle East

Israel

Hebrew

Saudi Arabia

English Arabic

Turkey

Turkish

United Arab Emirates

English Arabic
Other

Other Markets

Distributor Markets
Our Medicines
Medicines > Careers > Press Releases > Medical Information >

BMS at ECCO 2022

Intended for U.S. scientific audiences only.

The European Crohn’s and Colitis Organization (ECCO) 2022 Congress is an important opportunity to amplify the latest research and breakthroughs for patients with gastrointestinal (GI) immune-mediated diseases. 

Our Data at ECCO 2022

Read more about our key data being presented at the meeting.

At ECCO 2022, 10 company-sponsored abstracts will be presented, demonstrating our commitment to addressing unmet needs for patients living with GI immune-mediated diseases.

Our Science   

We are pursuing pathbreaking science and innovative research to potentially improve outcomes in GI immune-mediated diseases like inflammatory bowel disease (IBD), which includes ulcerative colitis and Crohn’s disease. Read how our scientists are addressing some of the most challenging diseases of our time, particularly in gastroenterology.

Winter’s story: living with ulcerative colitis >

Learn about Winter’s journey of living with ulcerative colitis for more than 20 years. 

Inflammatory bowel disease (IBD): research, partnerships and Bristol Myers Squibb’s dedication to patients – a Q&A with Mark Osterman >

Hear how experience as a physician is shaping the approach Mark Osterman, M.D, disease area head, Gastroenterology, is applying to IBD research.

Break the silence: shining a light on inflammatory bowel disease (IBD) >

Learn more from the European Federation of Crohn's & Ulcerative Colitis Associations (EFCCA) on how “breaking the silence” can make a lasting impact on IBD patients.

Understanding the needs of people living with inflammatory bowel disease (IBD) >

Learn how Bristol Myers Squibb is committed to ongoing research in inflammatory bowel disease.

Resources

Learn more about our research in IBD through the resources below.

S1P signaling fact sheet >

Learn about the role of sphingosine-1-phosphate (S1P) signaling and its relationship to gut inflammation.

TYK2 pathway fact sheet >

Learn about the scientific mechanism behind the tyrosine kinase 2 (TYK2) pathway and its role in immune-mediated diseases.

BMSscience.com

BMSscience.com is a resource for U.S. healthcare professionals to learn more about our recruiting clinical trials as well as the breadth of our research. 

IBD GAPPS

The IBD Global Assessment of Patient & Physician Unmet Needs Survey (GAPPS) is a resource for U.S. healthcare professionals to learn more about the impact of the evolving IBD treatment landscape on patients with ulcerative colitis and Crohn’s disease.

Crohn's disease fact sheet >

Learn more about Crohn’s disease, a GI immune-mediated disease that affects patients worldwide. 

Ulcerative colitis fact sheet >

Learn more about ulcerative colitis, its symptoms and effects on patients. 

Media Kit
media library

Media Library

Next Page Icon (Key Facts Sheets, Logos, Images) media contacts

Media Contacts

Next Page Icon